SK Bioscience

SK바이오사이언스 · 302440

Health Care Pharmaceuticals · KOSPI

Large-cap

Market cap US$2.3B (₩3.2T)

Overview

Company summary coming soon.

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$472M

▲ +143.5% YoY

Operating profit · FY2025

−US$89.5M

Loss narrowed

Net income · FY2025

−US$40.7M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$267.8M(₩369.5B)	US$193.9M(₩267.5B)	US$472M(₩651.4B)
Operating profit	−US$8.7M(−₩12B)	−US$100.3M(−₩138.4B)	−US$89.5M(−₩123.5B)
Net income	US$16.2M(₩22.3B)	−US$36.3M(−₩50.1B)	−US$40.7M(−₩56.2B)

Revenue

Operating profit

Net income

ROE

-2.8%

Debt/Eq

45.1%

Op. margin

-19.0%

Net margin

-8.6%

Rev. YoY

▲ +143.5%

Interactive price history isn't here yet. Would you use it?